CVE:RX - Biosyent Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
C$8.12 +0.06 (+0.74 %)
(As of 02/21/2019 04:00 PM ET)
Previous CloseC$8.06
Today's RangeC$8.06 - C$8.14
52-Week RangeC$6.93 - C$10.26
Volume2,623 shs
Average Volume7,177 shs
Market CapitalizationC$117.91 million
P/E Ratio21.48
Dividend YieldN/A
BetaN/A
BioSyent Inc., a specialty pharmaceutical company, acquires or in-licenses, develops, and sells various pharmaceutical and other healthcare products in Canada and internationally. The company's products include FeraMAX 150, an oral hematinic for the treatment of iron deficiency anaemia; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; Proktis-M, a rectal suppository designed to help healing of the anus and rectum; Aguettant System for pre-filled syringes that are used for various injectable medications in hospital and acute care settings; and Cysview for the detection and management of non-muscle invasive papillary bladder cancer. Its products also comprise Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis. In addition, it manufactures and markets Protect-It, a non-chemical food-safe grain insecticide product used in agriculture. BioSyent Inc. distributes its products to pharmacies and hospitals. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. is headquartered in Toronto, Canada.

Receive RX News and Ratings via Email

Sign-up to receive the latest news and ratings for RX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-905-2060013

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$21.52 million
Cash FlowC$1.56 per share
Book ValueC$1.83 per share

Profitability

Miscellaneous

EmployeesN/A
Market CapC$117.91 million
Next Earnings Date3/20/2019 (Estimated)
OptionableNot Optionable

Biosyent (CVE:RX) Frequently Asked Questions

What is Biosyent's stock symbol?

Biosyent trades on the Canadian Venture Exchange (CVE) under the ticker symbol "RX."

How were Biosyent's earnings last quarter?

Biosyent Inc. (CVE:RX) released its quarterly earnings data on Thursday, May, 25th. The company reported $0.06 EPS for the quarter, missing analysts' consensus estimates of $0.08 by $0.02. The business had revenue of $3.82 million for the quarter, compared to analysts' expectations of $4.80 million. View Biosyent's Earnings History.

When is Biosyent's next earnings date?

Biosyent is scheduled to release their next quarterly earnings announcement on Wednesday, March 20th 2019. View Earnings Estimates for Biosyent.

What price target have analysts set for RX?

2 equities research analysts have issued twelve-month target prices for Biosyent's stock. Their predictions range from C$11.00 to C$11.00. On average, they expect Biosyent's share price to reach C$11.00 in the next twelve months. This suggests a possible upside of 35.5% from the stock's current price. View Analyst Price Targets for Biosyent.

What is the consensus analysts' recommendation for Biosyent?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biosyent in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biosyent.

Has Biosyent been receiving favorable news coverage?

Media coverage about RX stock has trended positive on Thursday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Biosyent earned a media sentiment score of 2.3 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days.

Who are some of Biosyent's key competitors?

What other stocks do shareholders of Biosyent own?

Who are Biosyent's key executives?

Biosyent's management team includes the folowing people:
  • Mr. René C. Goehrum, Chairman, CEO & Pres
  • Mr. Kevin Wilson, VP of Community Health Bus.
  • Mr. Sharan Raghubir MBA, Director of the Hospital Bus. Unit - Biosyent Pharma Inc
  • Mr. Alfred D'Souza, Advisor
  • Mr. Robert March, VP of Fin. & CFO

How do I buy shares of Biosyent?

Shares of RX and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Biosyent's stock price today?

One share of RX stock can currently be purchased for approximately C$8.12.

How big of a company is Biosyent?

Biosyent has a market capitalization of C$117.91 million and generates C$21.52 million in revenue each year.

What is Biosyent's official website?

The official website for Biosyent is http://www.biosyent.com.

How can I contact Biosyent?

Biosyent's mailing address is 170 Attwell Dr Suite 520, ETOBICOKE, ON M9W 5Z5, Canada. The company can be reached via phone at +1-905-2060013.


MarketBeat Community Rating for Biosyent (CVE RX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  73 (Vote Outperform)
Underperform Votes:  65 (Vote Underperform)
Total Votes:  138
MarketBeat's community ratings are surveys of what our community members think about Biosyent and other stocks. Vote "Outperform" if you believe RX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel